mesothelioma

Merck reports positive data from malignant pleural mesothelioma trial
Merck reports positive data from malignant pleural mesothelioma trial
Clinical Trials Arena
Merck
Canadian Cancer Trials Group
clinical trials
Keytruda
mesothelioma
Flag link:
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Flag link:
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta
Fierce Pharma
Eagle Pharmaceuticals
Pemfexy
Eli Lilly
mesothelioma
non-small cell lung cancer
Flag link:
Atara, Memorial Sloan Kettering investigating patient death in phase 1 mesothelioma CAR-T study
Atara, Memorial Sloan Kettering investigating patient death in phase 1 mesothelioma CAR-T study
Fierce Biotech
Atara Biotherapeutics
clinical trials
mesothelioma
CAR-T
patient deaths
Flag link:
SITC: Cellectis' off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice
SITC: Cellectis' off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice
Fierce Biotech
Cellectis
CAR-T
cancer
pancreatic cancer
mesothelioma
SITC
Flag link:
Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate
Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate
Endpoints
Bristol Myers Squibb
Opdivo
Yervoy
mesothelioma
Flag link:
Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma
Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma
Motley Fool
Bristol-Myers Squibb
FDA
Opdivo
Yervoy
mesothelioma
Flag link:
Esmo 2020 – More encouraging signs for checkpoint bispecifics
Esmo 2020 – More encouraging signs for checkpoint bispecifics
EP Vantage
ESMO
bispecifics
Macrogenics
Akeso
mesothelioma
AK104
MGD019
Flag link:
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Fierce Pharma
WCLC
lung cancer
mesothelioma
Bristol-Myers Squibb
Opdivo
Yervoy
clinical trials
Flag link:
Targovax plans checkpoint combo trial after posting early data on oncolytic virus
Targovax plans checkpoint combo trial after posting early data on oncolytic virus
Fierce Biotech
Targovax
ONCOS-102
mesothelioma
clinical trials
Flag link:
Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta
Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta
Pharmaforum
Mylan
Eli Lilly
generics
Alimta
non-squamous non-small cell lung cancer
mesothelioma
Flag link:
Novocure Wins FDA Approval for First Mesothelioma Treatment in 15 Years
Novocure Wins FDA Approval for First Mesothelioma Treatment in 15 Years
BioSpace
Novocure
NovoTTF-100L
mesothelioma
Flag link:
Johnson & Johnson suffers another cancer-suit loss as talc case count climbs above 9,000
Johnson & Johnson suffers another cancer-suit loss as talc case count climbs above 9,000
Fierce Pharma
JNJ
lawsuit
mesothelioma
Flag link:
Novocure touts top-line data from Ph2 mesothelioma trial
Novocure touts top-line data from Ph2 mesothelioma trial
Drug Delivery Business News
Novocure
clinical trials
mesothelioma
humanitarian device exemption
tumor treating fields
devices
Flag link:
Why ImmunoGen, Inc. Jumped Higher Today
Why ImmunoGen, Inc. Jumped Higher Today
Motley Fool
Immunogen
anetumab ravtansine
Bayer
mesothelioma
Flag link:
Bayer misses in mesothelioma Phase 2
Bayer misses in mesothelioma Phase 2
BioPharma Dive
Bayer
mesothelioma
clinical trials
anetumab ravtansine
Flag link:
Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug
Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug
Endpoints
Bayer
clinical trials
anetumab ravtansine
mesothelioma
Flag link:
Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting
Yahoo
Five Prime
ASCO 2016
mesothelioma
FP-1039
Flag link:
GlaxoSmithKline dumps Five Prime's cancer drug in the midst of Phase I
GlaxoSmithKline dumps Five Prime's cancer drug in the midst of Phase I
Fierce Biotech
GSK
Five Prime
clinical trials
mesothelioma
Flag link:
AstraZeneca's mesothelioma drug fails monotherapy testing
AstraZeneca's mesothelioma drug fails monotherapy testing
BioPharma Dive
AstraZeneca
mesothelioma
clinical trials
tremelimumab
Flag link:

Pages